The Diabetes Vaccine & Immunotherapy Clinical Trials Tracker is a comprehensive real-time dashboard monitoring breakthrough prevention and treatment strategies for Type 1 diabetes. This platform tracks over 20 active clinical trials, including the landmark FDA-approved teplizumab (Tzield®)—the first disease-modifying therapy that delays T1D onset by approximately 2 years in high-risk individuals.
The tracker covers revolutionary BCG vaccine repurposing trials at Massachusetts General Hospital showing sustained HbA1c reduction for 8+ years through novel aerobic glycolysis mechanisms, the European DIAGNODE-3 Phase 3 trial testing precision medicine with GAD65-alum vaccine in HLA-specific patients, and TrialNet’s extensive portfolio including the PROTECT Phase 3 study demonstrating beta cell preservation in newly diagnosed patients.
Major trials span antigen-specific vaccines (GAD65, proinsulin, oral insulin), monoclonal antibodies (teplizumab, abatacept, rituximab), and cutting-edge cell therapies including autologous regulatory T cell infusions.
This dashboard represents the complete Type 1 diabetes immunotherapy landscape from prevention through established disease, tracking trials across all phases with over 14,000 participants enrolled globally.
The platform features interactive filtering by trial phase, intervention type (vaccine, antibody, cell therapy), and disease stage (prevention, new-onset, established T1D), with real-time enrollment progress visualization and hyperlinked access to trial registries and sponsor websites. Notable breakthroughs include teplizumab’s 2022 FDA approval marking a paradigm shift from treatment to prevention,
BCG’s century-old vaccine showing unprecedented infectious disease protection in T1D patients during COVID-19 alongside metabolic benefits, and emerging combination immunotherapy strategies learning from cancer immunotherapy successes.
The tracker encompasses TrialNet consortium studies, Massachusetts General Hospital’s 500+ patient BCG program, European precision medicine approaches, and planned future trials testing rational combinations like teplizumab plus GAD65 vaccine, providing researchers, clinicians, patients, and families with essential transparency into the transformative field of diabetes prevention and beta cell preservation.